Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty

NCT00667446 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT00667446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00667446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
January 31, 2013
Enrollment
72 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

central precocious puberty (cpp), depot formulation, gnrh analog, gonadotrophin-releasing hormone (gnrh), gonadotrophin-releasing hormone agonist (gnrha), leuprolide acetate, lupron, luteinizing hormone (lh), pediatrics central precocious puberty, precocious, suppression of lh, tanner staging